STOCKHOLM, Dec. 2, 2021 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) ("Sedana Medical" or "Company") hereby announces the Company's intention to, by exercise of the authorisation from the annual general meeting held 10 May 2021, carry out a directed issue of shares corresponding to approximately SEK 600 million to qualified and institutional investors in Sweden and internationally (the "Directed New Issue"). Sedana Medical has mandated Pareto Securities AB to evaluate the conditions for carrying out the Directed New Issue through a so-called accelerated book-building procedure. Successful completion of the intended Directed New Issue would not affect the Company's announced target to exceed SEK 500 million in net sales in Europe in the third year after EU approval (2024).